U.S. markets open in 5 hours 32 minutes
  • S&P Futures

    3,839.50
    -9.00 (-0.23%)
     
  • Dow Futures

    30,825.00
    -43.00 (-0.14%)
     
  • Nasdaq Futures

    13,441.25
    -34.25 (-0.25%)
     
  • Russell 2000 Futures

    2,152.30
    -8.70 (-0.40%)
     
  • Crude Oil

    52.70
    -0.07 (-0.13%)
     
  • Gold

    1,852.30
    -2.90 (-0.16%)
     
  • Silver

    25.40
    -0.09 (-0.35%)
     
  • EUR/USD

    1.2146
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.0400
    0.0000 (0.00%)
     
  • Vix

    23.59
    +1.68 (+7.67%)
     
  • GBP/USD

    1.3638
    -0.0038 (-0.28%)
     
  • USD/JPY

    103.7710
    +0.0150 (+0.01%)
     
  • BTC-USD

    31,866.92
    -501.37 (-1.55%)
     
  • CMC Crypto 200

    644.59
    -32.31 (-4.77%)
     
  • FTSE 100

    6,671.63
    +32.78 (+0.49%)
     
  • Nikkei 225

    28,546.18
    -276.11 (-0.96%)
     

What Percentage Of Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Do Insiders Own?

Simply Wall St
·5 min read

The big shareholder groups in Clinuvel Pharmaceuticals Limited (ASX:CUV) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

With a market capitalization of AU$1.1b, Clinuvel Pharmaceuticals is a decent size, so it is probably on the radar of institutional investors. In the chart below, we can see that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Clinuvel Pharmaceuticals.

Check out our latest analysis for Clinuvel Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Clinuvel Pharmaceuticals?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Clinuvel Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Clinuvel Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Clinuvel Pharmaceuticals. Looking at our data, we can see that the largest shareholder is BNY Mellon Asset Management with 9.7% of shares outstanding. For context, the second largest shareholder holds about 7.1% of the shares outstanding, followed by an ownership of 5.2% by the third-largest shareholder. Philippe Wolgen, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Clinuvel Pharmaceuticals

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own a reasonable proportion of Clinuvel Pharmaceuticals Limited. Insiders have a AU$171m stake in this AU$1.1b business. I would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public -- mostly retail investors -- own 54% of Clinuvel Pharmaceuticals. This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.

Private Company Ownership

We can see that Private Companies own 9.6%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Clinuvel Pharmaceuticals , and understanding them should be part of your investment process.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.